Department of Pulmonary Critical Care Medicine, Gazi University School of Medicine, Ankara, Turkey.
Ann Thorac Med. 2012 Apr;7(2):92-7. doi: 10.4103/1817-1737.94531.
Noninvasive ventilation (NIV) decreases mechanical ventilation indication in the early period of acute hypercapnic respiratory failure (AHcRF) and factors for success have been studied well. But, less is known about the factors influencing the NIV response in the subacute period. This study was aimed to determine the factors influencing the reduction of PaCO(2) levels within first 24 hours of therapy.
NIV response was defined as reduction of PaCO(2) level below 50 mmHg within first 24 hours. Patients with AHcRF, treated with NIV, were divided into 2 groups according to this criterion; group 1 as the nonresponsive, group 2 as the responsive. The differences in NIV methods and characteristics of the two groups were evaluated and compared in this retrospective study.
A total of 100 patients were included in the study; 66 of them in group 1 and 34 in group 2. No significant differences were identified between the length of NIV application and intensive care unit (ICU) stay, intubation and mortality rates, across the groups. Ninety-one percent of the patients in group 2 had received all night long NIV therapy; this was just 74% in group 1 (P=0.036). Results of multivariate analysis showed that while nocturnal application was significantly associated with better response, prior home ventilation and requirement of higher pressure support (PS) levels significantly and independently associated with poorer response to NIV therapy.
In patients with AHcRF, all night long use of NIV may accelerate healing by improving PaCO(2) reduction within the first 24 hours. A rapid response in PaCO(2) levels should not be expected in patients requiring higher PS levels and using prior home ventilation.
无创通气(NIV)可减少急性高碳酸血症性呼吸衰竭(AHcRF)早期的机械通气指征,并且已经很好地研究了成功的因素。但是,对于亚急性期影响 NIV 反应的因素知之甚少。本研究旨在确定影响治疗后 24 小时内 PaCO2 水平降低的因素。
将 NIV 反应定义为治疗后 24 小时内 PaCO2 水平降低 50mmHg 以下。将接受 NIV 治疗的 AHcRF 患者根据这一标准分为两组:组 1 为无反应组,组 2 为有反应组。在这项回顾性研究中,评估并比较了两组之间的 NIV 方法和特征差异。
共有 100 名患者纳入本研究;其中 66 名患者在组 1,34 名患者在组 2。两组之间的 NIV 应用时间和重症监护病房(ICU)入住时间、插管率和死亡率均无显著差异。组 2 中 91%的患者接受了整晚的 NIV 治疗;而组 1 中这一比例仅为 74%(P=0.036)。多变量分析结果表明,虽然夜间应用与更好的反应显著相关,但先前的家庭通气和需要更高的压力支持(PS)水平与对 NIV 治疗的反应较差显著且独立相关。
在 AHcRF 患者中,整晚使用 NIV 可能通过在最初 24 小时内加速 PaCO2 降低来加速康复。对于需要更高 PS 水平和先前使用家庭通气的患者,不应期望 PaCO2 水平快速降低。